Table: Mapping The Genome Companies
Pharmaceutical giants and biotech startups are mining the treasures in the human genome. Some key players: COMPANY STRATEGY HUMAN GENOME Sequencing almost all human genes, then hopes to SCIENCES develop drugs and diagnostics, mostly with partners. SMITHKLINE Invested $125 million in HGS to use its sequences to BEECHAM create new products. INCYTE Sequencing cDNA from many different tissues to find PHARMACEUTICAL interesting genes. Is selling access to its data. PFIZER Paid InCyte $25 million for access to database. UPJOHN Signed $20 million deal with InCyte for gene data. BRISTOL-MYERS Invested in SEQ and Cadus to develop new SQUIBB sequencing technology and drug screens. MILLENNIUM Searching for specific genes that cause obesity, diabetes, asthma, atherosclerosis, and cancer. HOFFMANN- Signed $70 million deal with Millennium. LAROCHE MERCK Paid Washington University to sequence 200,000 gene fragments. Makes data public. SEQUANA Searches family histories and HMO data for genes THERAPEUTICS that cause hypertension, asthma, and obesity. AMGEN Sequencing genes to find new drug targets. TAKEDA Uses SmithKline and HGS data to develop drugs. DATA: BUSINESS WEEK
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.